[go: up one dir, main page]

MX2021015500A - Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. - Google Patents

Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.

Info

Publication number
MX2021015500A
MX2021015500A MX2021015500A MX2021015500A MX2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A
Authority
MX
Mexico
Prior art keywords
pyrazines
glun2b receptor
substituted pyrazolo
receptor modulators
glun2b
Prior art date
Application number
MX2021015500A
Other languages
English (en)
Inventor
Curt Dvorak
Heather Coate
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021015500A publication Critical patent/MX2021015500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PIRAZOLO-PIRAZINAS sustituidas como ligandos del receptor GluN2B; tales compuestos pueden usarse en la modulación del receptor GluN2B y en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos, y afecciones mediadas por la actividad del receptor GluN2B.
MX2021015500A 2019-06-14 2020-06-12 Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. MX2021015500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861681P 2019-06-14 2019-06-14
PCT/EP2020/066405 WO2020249802A1 (en) 2019-06-14 2020-06-12 Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
MX2021015500A true MX2021015500A (es) 2022-02-10

Family

ID=71111400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015500A MX2021015500A (es) 2019-06-14 2020-06-12 Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.

Country Status (10)

Country Link
US (2) US11993587B2 (es)
EP (1) EP3983413A1 (es)
JP (1) JP2022536773A (es)
KR (1) KR20220024403A (es)
CN (1) CN114008052A (es)
AU (1) AU2020292994A1 (es)
BR (1) BR112021024117A2 (es)
CA (1) CA3143105A1 (es)
MX (1) MX2021015500A (es)
WO (1) WO2020249802A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
PE20220806A1 (es) 2019-06-14 2022-05-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b
MX2021015510A (es) 2019-06-14 2022-04-11 Janssen Pharmaceutica Nv Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
BR112021023562A2 (pt) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b
JOP20210328A1 (ar) 2019-06-14 2023-01-30 Janssen Pharmaceutica Nv مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
JP2022536773A (ja) * 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
EP4669318A1 (en) * 2023-02-23 2025-12-31 The Rockefeller University 1-ACYL-3-AMINOINDAZOLES FOR THE TREATMENT OF CYSTIC FIBROSIS
KR20250094560A (ko) 2023-12-15 2025-06-25 서울대학교산학협력단 GluN2B 억제제를 유효성분으로 포함하는 페닐케톤뇨증 및 고페닐알라닌혈증의 뇌기능 장애 예방, 개선 또는 치료용 조성물

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97888B (pt) 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
WO1998004534A1 (en) 1996-07-31 1998-02-05 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and medicinal compositions containing the same
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
AU2003214412A1 (en) 2002-03-28 2003-10-13 Eisai R & D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
JP2007504243A (ja) 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
RU2007110731A (ru) 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
ZA200704888B (en) 2004-11-22 2009-02-25 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
TWI443090B (zh) 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CA2697663A1 (en) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
MX2010009649A (es) 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
JPWO2009157196A1 (ja) 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
PL2308877T3 (pl) 2008-08-05 2014-07-31 Daiichi Sankyo Co Ltd Pochodne imidazopirydyn-2-onu
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
KR101048448B1 (ko) 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
WO2012102405A1 (ja) 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
AU2012286851A1 (en) 2011-07-28 2014-02-20 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2552836T3 (es) * 2011-09-19 2015-12-02 Sanofi N-[4-(1H-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos famacéuticos
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
BR112015021549A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
SMT201800650T1 (it) 2013-03-15 2019-01-11 Plexxikon Inc Composti eterociclici e loro impiego
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
EP3049417B1 (en) 2013-07-31 2018-10-17 Merck Patent GmbH Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
US9981950B2 (en) 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
HUE049278T2 (hu) 2014-08-15 2020-09-28 Janssen Pharmaceuticals Inc Pirazolok
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
WO2017007938A1 (en) * 2015-07-09 2017-01-12 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as glun2b receptor modulators
EA201891799A1 (ru) 2016-02-10 2019-02-28 Янссен Фармацевтика Нв Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
PE20220806A1 (es) 2019-06-14 2022-05-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
MX2021015510A (es) 2019-06-14 2022-04-11 Janssen Pharmaceutica Nv Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
BR112021023562A2 (pt) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b
JOP20210328A1 (ar) 2019-06-14 2023-01-30 Janssen Pharmaceutica Nv مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
PH12021553086A1 (en) 2019-06-14 2023-08-14 Debiopharm Int Sa Medicament and use thereof for treating bacterial infections involving biofilm
UY38806A (es) 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos
US20220348590A1 (en) * 2019-09-13 2022-11-03 The Board Institute, Inc. Cyclooxygenase-2 inhibitors and uses thereof
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders

Also Published As

Publication number Publication date
US11993587B2 (en) 2024-05-28
WO2020249802A1 (en) 2020-12-17
US11214563B2 (en) 2022-01-04
US20220315590A1 (en) 2022-10-06
CN114008052A (zh) 2022-02-01
CA3143105A1 (en) 2020-12-17
EP3983413A1 (en) 2022-04-20
BR112021024117A2 (pt) 2022-03-22
JP2022536773A (ja) 2022-08-18
US20200392113A1 (en) 2020-12-17
KR20220024403A (ko) 2022-03-03
AU2020292994A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
CR20210615A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2021015510A (es) Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
NZ737399A (en) Ccr2 modulators
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
WO2019193516A3 (en) Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
MX2021015511A (es) Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2022000712A (es) Moduladores de nlrp3.
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
PH12021552838A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators